-
1
-
-
0037398465
-
The epidemiology of epilepsy revisited
-
Sander JW. The epidemiology of epilepsy revisited. Curr Opin Neurol 2003;16:165-170
-
(2003)
Curr. Opin. Neurol.
, vol.16
, pp. 165-170
-
-
Sander, J.W.1
-
2
-
-
0034702511
-
Management of epilepsy in adolescents and adults
-
Brodie MJ, French JA. Management of epilepsy in adolescents and adults. Lancet 2000;356:323-329
-
(2000)
Lancet
, vol.356
, pp. 323-329
-
-
Brodie, M.J.1
French, J.A.2
-
3
-
-
72049122652
-
Definition of refractory epilepsy: Defining the indefinable
-
Kwan P, Brodie MJ. Definition of refractory epilepsy: Defining the indefinable? Lancet Neurol 2010;9:27-29
-
(2010)
Lancet Neurol.
, vol.9
, pp. 27-29
-
-
Kwan, P.1
Brodie, M.J.2
-
4
-
-
0032483972
-
KCNQ2 and KCNQ3 potassium channel subunits: Molecular correlates of the M-channel
-
Wang HS, Pan Z, Shi W, et al. KCNQ2 and KCNQ3 potassium channel subunits: Molecular correlates of the M-channel. Science 1998;282:1890-1893
-
(1998)
Science
, vol.282
, pp. 1890-1893
-
-
Wang, H.S.1
Pan, Z.2
Shi, W.3
-
5
-
-
27644518764
-
Pathways modulating neural kcnq/m KV7 potassium channels
-
Delmas P, Brown DA. Pathways modulating neural kcnq/m KV7 potassium channels. Nat Rev Neurosci 2005;6:850-862
-
(2005)
Nat. Rev. Neurosci.
, vol.6
, pp. 850-862
-
-
Delmas, P.1
Brown, D.A.2
-
7
-
-
0029088690
-
Reduction of spike frequency adaptation and blockade of M-current in rat CA1 pyramidal neurones by linopirdine (DuP 996), a neurotransmitter release enhancer
-
Aiken SP, Lampe BJ, Murphy PA, et al. Reduction of spike frequency adaptation and blockade of M-current in rat CA1 pyramidal neurones by linopirdine (DuP 996), a neurotransmitter release enhancer. Br J Pharmacol 1995;115:1163-1168
-
(1995)
Br. J. Pharmacol.
, vol.115
, pp. 1163-1168
-
-
Aiken, S.P.1
Lampe, B.J.2
Murphy, P.A.3
-
8
-
-
0027456560
-
Flupirtine a review of its pharmacological properties, and therapeutic efficacy in pain states
-
Friedel HA, Fitton A. Flupirtine. A review of its pharmacological properties, and therapeutic efficacy in pain states. Drugs 1993;45:548-569
-
(1993)
Drugs
, vol.45
, pp. 548-569
-
-
Friedel, H.A.1
Fitton, A.2
-
9
-
-
0029969951
-
D-23129: A new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures
-
Rostock A, Tober C, Rundfeldt C, et al. D-23129: A new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures. Epilepsy Res 1996;23:211-223
-
(1996)
Epilepsy Res.
, vol.23
, pp. 211-223
-
-
Rostock, A.1
Tober, C.2
Rundfeldt, C.3
-
10
-
-
0029891002
-
D-23129: A potent anticonvulsant in the amygdala kindling model of complex partial seizures
-
Tober C, Rostock A, Rundfeldt C, et al. D-23129: A potent anticonvulsant in the amygdala kindling model of complex partial seizures. Eur J Pharmacol 1996;303:163-169
-
(1996)
Eur. J. Pharmacol.
, vol.303
, pp. 163-169
-
-
Tober, C.1
Rostock, A.2
Rundfeldt, C.3
-
11
-
-
0033032546
-
Effects of retigabine (D-23129) on different patterns of epileptiform activity induced by 4-aminopyridine in rat entorhinal cortex hippocampal slices
-
Armand V, Rundfeldt C, Heinemann U. Effects of retigabine (D-23129) on different patterns of epileptiform activity induced by 4-aminopyridine in rat entorhinal cortex hippocampal slices. Naunyn Schmiedebergs Arch Pharmacol 1999;359:33-39
-
(1999)
Naunyn Schmiedebergs Arch. Pharmacol.
, vol.359
, pp. 33-39
-
-
Armand, V.1
Rundfeldt, C.2
Heinemann, U.3
-
12
-
-
0033989219
-
Effects of retigabine (D-23129) on different patterns of epileptiform activity induced by low magnesium in rat entorhinal cortex hippocampal slices
-
Armand V, Rundfeldt C, Heinemann U. Effects of retigabine (D-23129) on different patterns of epileptiform activity induced by low magnesium in rat entorhinal cortex hippocampal slices. Epilepsia 2000;41:28-33
-
(2000)
Epilepsia
, vol.41
, pp. 28-33
-
-
Armand, V.1
Rundfeldt, C.2
Heinemann, U.3
-
13
-
-
0033402130
-
The anticonvulsant retigabine potently suppresses epileptiform discharges in the low Ca2+ and low Mg2+ model in the hippocampal slice preparation
-
Dost R, Rundfeldt C. The anticonvulsant retigabine potently suppresses epileptiform discharges in the low Ca2+ and low Mg2+ model in the hippocampal slice preparation. Epilepsy Res 2000;38:53-66
-
(2000)
Epilepsy Res.
, vol.38
, pp. 53-66
-
-
Dost, R.1
Rundfeldt, C.2
-
14
-
-
18844476488
-
Effects of retigabine on rhythmic synchronous activity of human neocortical slices
-
Straub H, Kohling R, Hohling J, et al. Effects of retigabine on rhythmic synchronous activity of human neocortical slices. Epilepsy Res 2001;44:155-165
-
(2001)
Epilepsy Res.
, vol.44
, pp. 155-165
-
-
Straub, H.1
Kohling, R.2
Hohling, J.3
-
15
-
-
4544384631
-
Mice carrying the szt1 mutation exhibit increased seizure susceptibility and altered sensitivity to compounds acting at the m-channel
-
Otto JF, Yang Y, Frankel WN, et al. Mice carrying the szt1 mutation exhibit increased seizure susceptibility and altered sensitivity to compounds acting at the m-channel. Epilepsia 2004;45:1009-1016
-
(2004)
Epilepsia
, vol.45
, pp. 1009-1016
-
-
Otto, J.F.1
Yang, Y.2
Frankel, W.N.3
-
16
-
-
64949142097
-
Isobolographic characterization of interactions of retigabine with carbamazepine, lamotrigine, and valproate in the mouse maximal electroshock-induced seizure model
-
Luszczki JJ, Wu JZ, Raszewski G, Czuczwar SJ. Isobolographic characterization of interactions of retigabine with carbamazepine, lamotrigine, and valproate in the mouse maximal electroshock-induced seizure model. Naunyn Schmiedebergs Arch Pharmacol 2009;379:163-179
-
(2009)
Naunyn Schmiedebergs Arch. Pharmacol.
, vol.379
, pp. 163-179
-
-
Luszczki, J.J.1
Wu, J.Z.2
Raszewski, G.3
Czuczwar, S.J.4
-
17
-
-
21344462822
-
A potassium channel, the M-channel, as a therapeutic target
-
Surti TS, Jan LY. A potassium channel, the M-channel, as a therapeutic target. Curr Opin Investig Drugs 2005;6:704-711
-
(2005)
Curr. Opin. Investig Drugs
, vol.6
, pp. 704-711
-
-
Surti, T.S.1
Jan, L.Y.2
-
18
-
-
0037462422
-
The anticonvulsant retigabine attenuates nociceptive behaviours in rat models of persistent and neuropathic pain
-
Blackburn-Munro G, Jensen BS. The anticonvulsant retigabine attenuates nociceptive behaviours in rat models of persistent and neuropathic pain. Eur J Pharmacol 2003;460:109-116
-
(2003)
Eur. J. Pharmacol.
, vol.460
, pp. 109-116
-
-
Blackburn-Munro, G.1
Jensen, B.S.2
-
19
-
-
34547841517
-
The neuronal KCNQ channel opener retigabine inhibits locomotor activity and reduces forebrain excitatory responses to the psychostimulants cocaine, methylphenidate and phencyclidine
-
Hansen HH, Andreasen JT, Weikop P, et al. The neuronal KCNQ channel opener retigabine inhibits locomotor activity and reduces forebrain excitatory responses to the psychostimulants cocaine, methylphenidate and phencyclidine. Eur J Pharmacol 2007;570:77-88
-
(2007)
Eur. J. Pharmacol.
, vol.570
, pp. 77-88
-
-
Hansen, H.H.1
Andreasen, J.T.2
Weikop, P.3
-
20
-
-
52049097593
-
The mechanisms of neurodegenerative processes and current pharmacotherapy of Alzheimer's disease
-
Gongadze N, Antelava N, Kezeli T, et al. The mechanisms of neurodegenerative processes and current pharmacotherapy of Alzheimer's disease. Georgian Med News 2008;155:44-48
-
(2008)
Georgian Med. News
, vol.155
, pp. 44-48
-
-
Gongadze, N.1
Antelava, N.2
Kezeli, T.3
-
21
-
-
0033011118
-
Characterization of the K+ channel opening effect of the anticonvulsant retigabine in pc12 cells
-
Rundfeldt C. Characterization of the K+ channel opening effect of the anticonvulsant retigabine in pc12 cells. Epilepsy Res 1999;35:99-107
-
(1999)
Epilepsy Res.
, vol.35
, pp. 99-107
-
-
Rundfeldt, C.1
-
22
-
-
0034677733
-
The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells tranfected with human KCNQ2/3 subunits
-
Rundfeldt C, Netzer R. The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells tranfected with human KCNQ2/3 subunits. Neurosci Lett 2000B;282:73-76
-
(2000)
Neurosci Lett.
, vol.282
, pp. 73-76
-
-
Rundfeldt, C.1
Netzer, R.2
-
23
-
-
0033862433
-
Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels
-
Wickenden AD, Yu W, Zou A, et al. Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels. Mol Pharmacol 2000;58:591-600
-
(2000)
Mol. Pharmacol.
, vol.58
, pp. 591-600
-
-
Wickenden, A.D.1
Yu, W.2
Zou, A.3
-
24
-
-
0033916576
-
Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine
-
Main MJ, Cryan JE, Dupere JR, et al. Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine Mol Pharmacol 2000;58:253-262
-
(2000)
Mol. Pharmacol.
, vol.58
, pp. 253-262
-
-
Main, M.J.1
Cryan, J.E.2
Dupere, J.R.3
-
25
-
-
0035425653
-
Activation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anti-convulsant drug retigabine
-
Tatulian L, Delmas P, Abogadie FC, et al. Activation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anti-convulsant drug retigabine. J Neurosci 2001;21:5535-5545
-
(2001)
J. Neurosci.
, vol.21
, pp. 5535-5545
-
-
Tatulian, L.1
Delmas, P.2
Abogadie, F.C.3
-
26
-
-
27644518764
-
Pathways modulating neural kcnq/m (KV7) potassium channels
-
Delmas P, Brown DA. Pathways modulating neural kcnq/m (KV7) potassium channels. Nat Rev Neurosci 2005;6:850-862
-
(2005)
Nat. Rev. Neurosci.
, vol.6
, pp. 850-862
-
-
Delmas, P.1
Brown, D.A.2
-
28
-
-
0034303612
-
Neuronal KCNQ potassium channels: Physiology and role in disease
-
Jentsch TJ. Neuronal KCNQ potassium channels: Physiology and role in disease. Nat Rev Neurosci 2000;1:21-30
-
(2000)
Nat. Rev. Neurosci.
, vol.1
, pp. 21-30
-
-
Jentsch, T.J.1
-
29
-
-
15744400656
-
The new anticonvulsant retigabine favors voltage-dependent opening of the KV7.2 (KCNQ2) channel by binding to its activation gate
-
Wuttke TV, Seebohm G, Bail S, et al. The new anticonvulsant retigabine favors voltage-dependent opening of the KV7.2 (KCNQ2) channel by binding to its activation gate. Mol Pharmacol 2005;67:1009-1017
-
(2005)
Mol. Pharmacol.
, vol.67
, pp. 1009-1017
-
-
Wuttke, T.V.1
Seebohm, G.2
Bail, S.3
-
30
-
-
19044386394
-
Molecular determinants of KCNQ (KV7) K+ channel sensitivity to the anticonvulsant retigabine
-
Schenzer A, Friedrich T, Pusch M, et al. Molecular determinants of KCNQ (KV7) K+ channel sensitivity to the anticonvulsant retigabine. J Neurosci 2005;25:5051-5060
-
(2005)
J. Neurosci.
, vol.25
, pp. 5051-5060
-
-
Schenzer, A.1
Friedrich, T.2
Pusch, M.3
-
31
-
-
59449092002
-
Refinement of the binding site and mode of action of the anticonvulsant Retigabine on KCNQ K+ channels
-
Lange W, Geissendorfer J, Schenzer A, et al. Refinement of the binding site and mode of action of the anticonvulsant Retigabine on KCNQ K+ channels. Mol Pharmacol 2009;75:272-280
-
(2009)
Mol. Pharmacol.
, vol.75
, pp. 272-280
-
-
Lange, W.1
Geissendorfer, J.2
Schenzer, A.3
-
32
-
-
0036210933
-
Effects of the anticonvulsant retigabine on cultured cortical neurons: Changes in electroresponsive properties and synaptic transmission
-
Otto JF, Kimball MM, Wilcox KS. Effects of the anticonvulsant retigabine on cultured cortical neurons: Changes in electroresponsive properties and synaptic transmission. Mol Pharmacol 2002;61:921-927
-
(2002)
Mol. Pharmacol.
, vol.61
, pp. 921-927
-
-
Otto, J.F.1
Kimball, M.M.2
Wilcox, K.S.3
-
33
-
-
0034533728
-
Investigations into the mechanism of action of the new anticonvulsant retigabine interaction with GABAergic and glutamatergic neurotransmission and with voltage gated ion channels
-
Rundfeldt C, Netzer R. Investigations into the mechanism of action of the new anticonvulsant retigabine. Interaction with GABAergic and glutamatergic neurotransmission and with voltage gated ion channels. Arzneimittelforschung 2000A;50:1063-1070
-
(2000)
Arzneimittelforschung
, vol.50
, pp. 1063-1070
-
-
Rundfeldt, C.1
Netzer, R.2
-
34
-
-
0038293217
-
Pharmacokinetic interaction between retigabine and lamotrigine in healthy subjects
-
Hermann R, Knebel NG, Niebch G, et al. Pharmacokinetic interaction between retigabine and lamotrigine in healthy subjects. Eur J Clin Pharmacol 2003A;58:795-802
-
(2003)
Eur. J. Clin. Pharmacol.
, vol.58
, pp. 795-802
-
-
Hermann, R.1
Knebel, N.G.2
Niebch, G.3
-
35
-
-
0036152375
-
Multiple-dose, linear, dose-proportional pharmacokinetics of retigabine in healthy volunteers
-
Ferron GM, Paul J, Fruncillo R, et al. Multiple-dose, linear, dose-proportional pharmacokinetics of retigabine in healthy volunteers. J Clin Pharmacol 2002;42:175-182
-
(2002)
J. Clin. Pharmacol.
, vol.42
, pp. 175-182
-
-
Ferron, G.M.1
Paul, J.2
Fruncillo, R.3
-
36
-
-
0037261396
-
Effects of age and sex on the disposition of retigabine
-
Hermann R, Ferron GM, Erb K, et al. Effects of age and sex on the disposition of retigabine. Clin Pharmacol Ther 2003B;73:61-70
-
(2003)
Clin. Pharmacol. Ther.
, vol.73
, pp. 61-70
-
-
Hermann, R.1
Ferron, G.M.2
Erb, K.3
-
37
-
-
0037660846
-
Lack of pharmacokinetic interaction between retigabine and phenobarbitone at steady-state in healthy subjects
-
Ferron GM, Patat A, Parks V, et al. Lack of pharmacokinetic interaction between retigabine and phenobarbitone at steady-state in healthy subjects. Br J Clin Pharmacol 2003;56:39-45
-
(2003)
Br. J. Clin. Pharmacol.
, vol.56
, pp. 39-45
-
-
Ferron, G.M.1
Patat, A.2
Parks, V.3
-
38
-
-
80051777786
-
Retigabine
-
BIALER M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS
-
Hammond JMJ. Retigabine. In: BIALER M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS, Epilepsy Res 2010;92:113-116
-
(2010)
Epilepsy Res.
, vol.92
, pp. 113-116
-
-
Hammond, J.M.J.1
-
39
-
-
80051742205
-
Retigabine
-
BIALER M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS
-
Mansbach H. Retigabine. In: BIALER M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS, Epilepsy Res 2009;83:27-31
-
(2009)
Epilepsy Res.
, vol.83
, pp. 27-31
-
-
Mansbach, H.1
-
40
-
-
0038084973
-
Pharmacokinetic interaction between valproic acid, topiramate, phenytoin or carbamazepine and retigabine in epileptic patients
-
Ferron GM, Sachdeo R, Partiot A, et al. Pharmacokinetic interaction between valproic acid, topiramate, phenytoin or carbamazepine and retigabine in epileptic patients. Clin Pharmacol Ther 2001;69:P18
-
(2001)
Clin. Pharmacol. Ther.
, vol.69
-
-
Ferron, G.M.1
Sachdeo, R.2
Partiot, A.3
-
41
-
-
0030991641
-
In vitro glucuronidation of D-23129, a new anticonvulsant, by human liver microsomes and liver slices
-
McNeilly PJ, Torchin CD, Anderson LW, et al. In vitro glucuronidation of D-23129, a new anticonvulsant, by human liver microsomes and liver slices. Xenobiotica 1997;27:431-441
-
(1997)
Xenobiotica
, Issue.27
, pp. 431-441
-
-
McNeilly, P.J.1
Torchin, C.D.2
Anderson, L.W.3
-
42
-
-
0032930073
-
Metabolism of retigabine (D-23129), a novel anticonvulsant
-
Hempel R, Schupke H, McNeilly PJ, et al. Metabolism of retigabine (D-23129), a novel anticonvulsant. Drug Metab Dispos 1999;27:613-622
-
(1999)
Drug Metab. Dispos.
, vol.27
, pp. 613-622
-
-
Hempel, R.1
Schupke, H.2
McNeilly, P.J.3
-
43
-
-
0032906655
-
Retigabine N-glucuronidation and its potential role in enterohepatic circulation
-
Hiller A, Nguyen N, Strassburg CP, et al. Retigabine N-glucuronidation and its potential role in enterohepatic circulation. Drug Metab Dispos 1999;27:605-612
-
(1999)
Drug Metab. Dispos
, vol.27
, pp. 605-612
-
-
Hiller, A.1
Nguyen, N.2
Strassburg, C.P.3
-
44
-
-
33646497843
-
N-Glucuronidation of the antiepileptic drug retigabine: Results from studies with human volunteers, heterologously expressed human UGTs, human liver, kidney, and liver microsomal membranes of Crigler-Najjar type II
-
Borlak J, Gasparic A, Locher M, et al. N-Glucuronidation of the antiepileptic drug retigabine: Results from studies with human volunteers, heterologously expressed human UGTs, human liver, kidney, and liver microsomal membranes of Crigler-Najjar type II. Metabolism 2006;55:711-721
-
(2006)
Metabolism
, vol.55
, pp. 711-721
-
-
Borlak, J.1
Gasparic, A.2
Locher, M.3
-
45
-
-
33744543460
-
The role of Gilbert's syndrome and frequent NAT2 slow acetylation polymorphisms in the pharmacokinetics of retigabine
-
Hermann R, Borlak J, Munzel U, et al. The role of Gilbert's syndrome and frequent NAT2 slow acetylation polymorphisms in the pharmacokinetics of retigabine. Pharmacogenomics 2006;6:211-219
-
(2006)
Pharmacogenomics
, vol.6
, pp. 211-219
-
-
Hermann, R.1
Borlak, J.2
Munzel, U.3
-
46
-
-
80051717855
-
Retigabine
-
French J, Porter A, Nohria V. Retigabine. In: BIALER M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T, Epilepsy Res 2004;61:10-12
-
(2004)
Epilepsy Res.
, vol.61
, pp. 10-12
-
-
French, J.1
Porter, A.2
Nohria, V.3
Bialer, M.4
Johannessen, S.I.5
Kupferberg, H.J.6
Levy, R.H.7
Perucca, E.8
Tomson, T.9
-
47
-
-
34247252905
-
Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures
-
Porter RJ, Partiot A, Sachdeo R, et al. Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures. Neurology 2007;68:1197-1204
-
(2007)
Neurology
, vol.68
, pp. 1197-1204
-
-
Porter, R.J.1
Partiot, A.2
Sachdeo, R.3
-
48
-
-
78649984382
-
Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy
-
Brodie MJ, Lerche H, Gil-Nagel A, et al. Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy. Neurology 2010;75:1817-1824
-
(2010)
Neurology
, vol.75
, pp. 1817-1824
-
-
Brodie, M.J.1
Lerche, H.2
Gil-Nagel, A.3
-
49
-
-
79955592696
-
Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy
-
French JA, Abou-Khalil BW, Leroy RF, et al. Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy. Neurology 2011;76:1555-1563
-
(2011)
Neurology
, vol.76
, pp. 1555-1563
-
-
French, J.A.1
Abou-Khalil, B.W.2
Leroy, R.F.3
-
50
-
-
84859428190
-
The urinary safety profile and secondary renal effects of retigabine (ezogabine): A first-in-class antiepileptic drug that targets KCNQ (Kv7) potassium channels
-
Brickel N, Gandhi P, Vanlandingham K, et al. The urinary safety profile and secondary renal effects of retigabine (ezogabine): A first-in-class antiepileptic drug that targets KCNQ (Kv7) potassium channels. Epilepsia 2012;53:606-612
-
(2012)
Epilepsia
, Issue.53
, pp. 606-612
-
-
Brickel, N.1
Gandhi, P.2
Vanlandingham, K.3
-
51
-
-
84872215939
-
Advisory committee meeting to discuss antiepileptic drugs (aeds) and suicidality
-
Available from FDA Katz. pdf
-
Katz R. Advisory Committee Meeting to Discuss Antiepileptic Drugs (AEDs) and Suicidality. Memorandum. Available from: Http://www.fda.gov/ohrms/dockets/ ac/08/briefing/2008-4372b1-01-FDAKatz. pdf) 2008
-
(2008)
Memorandum
-
-
Katz, R.1
-
52
-
-
77955291604
-
Suicide-related events in patients treated with antiepileptic drugs
-
Arana A, Wentworth CE, Ayuso-Mateos JL, et al. Suicide-related events in patients treated with antiepileptic drugs. N Engl J Med 2010;363:542-551
-
(2010)
N. Engl. J. Med.
, vol.363
, pp. 542-551
-
-
Arana, A.1
Wentworth, C.E.2
Ayuso-Mateos, J.L.3
-
53
-
-
0035122602
-
Characterization of KCNQ5/Q3 potassium channels expressed in mammalian cells
-
Wickenden AD, Zou A, Wagoner PK, et al. Characterization of KCNQ5/Q3 potassium channels expressed in mammalian cells. Br J Pharmacol 2001;132:381-384
-
(2001)
Br. J. Pharmacol.
, vol.132
, pp. 381-384
-
-
Wickenden, A.D.1
Zou, A.2
Wagoner, P.K.3
-
54
-
-
85047690079
-
An introduction to antiepileptic drugs
-
Perucca E. An introduction to antiepileptic drugs. Epilepsia 2005;46:31-37
-
(2005)
Epilepsia
, vol.46
, pp. 31-37
-
-
Perucca, E.1
-
55
-
-
0030975686
-
Lamotrigine substitution study: Evidence for synergism with sodium valproate
-
105 Study Group
-
Brodie MJ, Yuen AW. Lamotrigine substitution study: Evidence for synergism with sodium valproate? 105 Study Group. Epilepsy Res 1997;26:423-432
-
(1997)
Epilepsy Res.
, vol.26
, pp. 423-432
-
-
Brodie, M.J.1
Yuen, A.W.2
-
56
-
-
0032799794
-
The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: Evidence for a pharmacodynamic interaction
-
Pisani F, Oteri G, Russo MF, et al. The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: Evidence for a pharmacodynamic interaction. Epilepsia 1999;40:1141-1146
-
(1999)
Epilepsia
, vol.40
, pp. 1141-1146
-
-
Pisani, F.1
Oteri, G.2
Russo, M.F.3
-
57
-
-
80051547306
-
Antiepileptic drug therapy: Does mechanism of action matter
-
Brodie MJ, Covanis A, Gil-Nagel A, et al. Antiepileptic drug therapy: Does mechanism of action matter? Epilepsy Behav 2011;21:331-341
-
(2011)
Epilepsy Behav.
, vol.21
, pp. 331-341
-
-
Brodie, M.J.1
Covanis, A.2
Gil-Nagel, A.3
-
58
-
-
5444225675
-
Urodynamic effects of the K+ channel (KCNQ) opener retigabine in freely moving, conscious rats
-
Streng T, Christoph T, Andersson KE. Urodynamic effects of the K+ channel (KCNQ) opener retigabine in freely moving, conscious rats. J Urol 2004;72:2054-2058
-
(2004)
J. Urol.
, vol.72
, pp. 2054-2058
-
-
Streng, T.1
Christoph, T.2
Andersson, K.E.3
|